Evidence map›Paper›PMID 32978337›Full record

ReviewPostgraduate medical journal2021

COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment.

Anant Parasher

Full text readReview
In one paragraph

Review in Postgraduate medical journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 361 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
361citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

361 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

301 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Anant ParasherMedicine, Guru Teg Bahadur Hospital, New Delhi, India anant02jan@gmail.com.ORCID http://orcid.org/0000-0002-5573-3231

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe severe acute respiratory syndrome (SARS) coronavirus-2 is a novel coronavirus belonging to the family Coronaviridae and is now known to be responsible for the outbreak of a series of recent acute atypical respiratory infections originating in Wuhan, China. The disease caused by this virus, termed coronavirus disease 19 or simply COVID-19, has rapidly spread throughout the world at an alarming pace and has been declared a pandemic by the WHO on March 11, 2020. In this review, an update on the pathophysiology, clinical presentation and the most recent management strategies for COVID-19 has been described. MATERIALS AND

methodsA search was conducted for literature and various articles/case reports from 1997 to 2020 in PUBMED/MEDLINE for the keywords coronavirus, SARS, Middle East respiratory syndrome and mRNA virus. RESULTS AND

conclusionsCOVID-19 has now spread globally with increasing morbidity and mortality among all populations. In the absence of a proper and effective antibody test, the diagnosis is presently based on a reverse-transcription PCR of nasopharyngeal and oropharyngeal swab samples. The clinical spectrum of the disease presents in the form of a mild, moderate or severe illness. Most patients are either asymptomatic carriers who despite being without symptoms have the potential to be infectious to others coming in close contact, or have a mild influenza-like illness which cannot be differentiated from a simple upper respiratory tract infection. Moderate and severe cases require hospitalisation as well as intensive therapy which includes non-invasive as well as invasive ventilation, along with antipyretics, antivirals, antibiotics and steroids. Complicated cases may require treatment by immunomodulatory drugs and plasma exchange therapy. The search for an effective vaccine for COVID-19 is presently in full swing, with pharmaceutical corporations having started human trials in many countries.

Indexed as

Anti-Bacterial AgentsAnticoagulantsAntiviral AgentsCOVID-19COVID-19 TestingGlucocorticoidsHumansPlasma ExchangeReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionSARS-CoV-2Severe Acute Respiratory SyndromeShock, SepticVirus AttachmentVirus InternalizationAnti-Bacterial AgentsAnticoagulantsAntiviral AgentsGlucocorticoidsVirology

Identifiers

PMID32978337
PMCPMC10017004

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read47
identifiers read1
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.